Floatz logo

Therapeutic Asset Ratings

6,371 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Pembrolizumab
Kidney Cancer
Essen BiotechP4BB (65)
Pozelimab
CHAPLE Disease
Regeneron PharmaceuticalsP4BB (65)
Talquetamab
Waldenstrom Macroglobulinemia
Anne Louise Tølbøll SørensenP4BB (65)
Teclistamab
Waldenstrom Macroglobulinemia
Anne Louise Tølbøll SørensenP4BB (65)
Tislelizumab
Hepatocellular Carcinoma
Haibo ShaoP4BB (65)
Tislelizumab
Neoadjuvant Therapy
Seventh Medical Center of PLA General HospitalP4BB (65)
Tislelizumab
Small Cell Lung Carcinoma
BeOne MedicinesP4BB (65)
Atezolizumab
Small Cell Lung Carcinoma
Washington University School of MedicineP3BB (65)
Benmelstobart
Non-Small Cell Lung Carcinoma
The Third Xiangya Hospital of Central South UniversityP3BB (65)
Cetuximab
Metastasis From Malignant Tumor Of Colon
Shanghai 6th People's HospitalP3BB (65)
DARATUMUMAB
Smoldering Plasma Cell Myeloma
Regeneron PharmaceuticalsP3BB (65)
Dostarlimab
Ovarian Carcinoma
University of WashingtonP3BB (65)
Dostarlimab
Neoplasms, Colon
GlaxoSmithKlineP3BB (65)
Epcoritamab
Diffuse Large B-Cell Lymphoma
Mwanasha Merrill, MDP3BB (65)
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Hepatocellular Carcinoma
Fudan UniversityP3BB (65)
immunoglobulin G1-kappa, anti-[Fucosyl-GM1 (fucosylated monosialoganglioside 1)], Homo sapiens monoclonal antibody; H-gamma1 heavy chain Homo sapiens (1-452) [VH (Homo sapiens IGHV3-48*02 (90.7%) -(IGHD) -IGHJ3*01 (92.3%) M123>T (117), CDR-IMGT [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo sapiens IGHG1*03 (100%), G1m3, nG1m1 CH1 R120, CH3 E12, M14 (CH1 R120 (219) (123-220), hinge 1-15 (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1D-16*01 (100%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (231-231'':234-234'')-bisdisulfide, produced in a Chinese hamster ovary (CHO) cell line lacking the enzyme alpha-(1,6)-fucosyltransferase (FUT8), glycoform alfa
Small Cell Lung Carcinoma
Bristol-Myers SquibbP3BB (65)
Mosunetuzumab
Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP3BB (65)
Nivolumab
Classic Hodgkin Lymphoma
National Cancer Institute (NCI)P3BB (65)
Nivolumab
Classic Hodgkin Lymphoma
National Cancer Institute (NCI)P3BB (65)
Nivolumab
Hepatocellular Carcinoma
Zhejiang Haichang Biotech Co., Ltd.P3BB (65)
Nivolumab
Bladder Transitional Cell Carcinoma
Nagoya UniversityP3BB (65)
Nivolumab
Uveal Melanoma
Inge Marie SvaneP3BB (65)
Nivolumab
Primary Mediastinal Large B-Cell Lymphoma
St. Petersburg State Pavlov Medical UniversityP3BB (65)
Nivolumab
Sarcomatoid Renal Cell Carcinoma
City of Hope Medical CenterP3BB (65)
Pembrolizumab
Adenocarcinoma
M.D. Anderson Cancer CenterP3BB (65)
Showing 351 to 375 of 6,371 assets
PreviousPage 15 of 255Next